Therapeutic Touch®

• Preclinical evidence testing a drug, a procedure, or another medical treatment in isolated cells or in animals; preclinical evidence is considered only an initial indication of possible effects in people only of anticancer activity with osteosarcoma

See Are you a health professional? ›

What is your body terrain? ›

• Preliminary evidencesignificant effects in small or poorly designed clinical studies OR conflicting results in adequate studies but a preponderance of evidence of an effect (this is the CancerChoices definition; other researchers and studies may define this differently) of lower cortisol levels after vascular surgery among people treated with TT
• Preliminary evidence of a higher marker of immune activation after vascular surgery among people treated with TT

See How can Therapeutic Touch® help you? What the research says ›

• Preliminary evidence of less fatigue  during chemotherapy among women with cancer treated with TT
• Preliminary evidence of less nausea and vomiting during chemotherapy among people with breast cancer treated with TT
• Preliminary (conflicting) evidence of less pain among people with cancer treated with TT
• Preliminary evidence of greater well-being among people with terminal cancer treated with TT
• Insufficient (conflicting) evidencepreclinical evidence only OR clinical studies with such poor or unclear methodology that no conclusion can be drawn OR conflicting findings across clinical studies with no preponderance of evidence in one direction; conflicting evidence occurs when studies find conflicting effects (positive effect vs no effect or negative effect) with the same treatment and the same general study population (same cancer type, for example) (this is the CancerChoices definition; other researchers and studies may define this differently) of less anxiety among people with cancer treated with TT

See How can Therapeutic Touch® help you? What the research says ›

We did not find any published studies investigating Therapeutic Touch® for reducing cancer risk.

• Strong recommendation for use in one clinical practice guideline

See How do experts use Therapeutic Touch® ›

• Generally safe, with no known safety concerns

• Widely available without restriction
• Inexpensive (less than $500 US/year, depending on frequency of use)

See Affordability and access ›